Physician

Makenzi Colleen Evangelist, M.D.

According to 2025 Medicare claims, Makenzi Evangelist, M.D. (NPI: 1578724126) practices medical oncology in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is NEW YORK ONCOLOGY HEMATOLOGY, P.C. (NPI: 1609863448; TIN: 141799724) and primary practice location at 12206-5012. Evangelist is affiliated with the Trinity Health Integrated Care (ACO ID: A3454), participating under the MSSP model.

Evangelist's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 584 traditional Medicare patients, billed 62,144 HCPCS/CPT codes, and received $1,220,977 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 933 prescription claims across 152 beneficiaries totaling $1,344,248 in drug costs, led by Tagrisso (Osimertinib Mesylate). 2023 DME data shows 12 claims. Open Payments data shows 83 records totaling $1,058,536. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $631,678 to $1,220,977. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $398,463 to $1,344,248. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,199 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	380	61,085	$631,678
2016	424	43,596	$714,431
2017	498	53,046	$1,144,978
2018	426	42,465	$880,964
2019	375	35,459	$955,298
2020	547	54,367	$1,264,627
2021	490	49,023	$1,115,665
2022	522	57,359	$1,087,465
2023	524	63,173	$1,139,033
2024	584	62,144	$1,220,977

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	175	1,132	$398,463
2016	204	1,421	$667,179
2017	223	1,395	$774,291
2018	269	1,580	$980,789
2019	201	1,393	$1,075,878
2020	183	1,148	$1,252,389
2021	174	1,257	$1,678,757
2022	177	1,207	$1,465,609
2023	158	1,060	$1,870,321
2024	152	933	$1,344,248

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	44	$2,178
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	27	$650
2019	N/R	14	$3,349
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	12	$6,766
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	173	355	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	103	110	$55
80053	Blood test, comprehensive group of blood chemicals	326	545	$10
36415	Insertion of needle into vein for collection of blood sample	337	537	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	346	572	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	25	750	$400,362
Lorbrena	Lorlatinib	12	360	$257,619
Alecensa	Alectinib Hcl	13	390	$127,640
Eliquis	Apixaban	71	2,670	$51,126
Exemestane	Exemestane	23	1,650	$4,365

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$4,351	Rigel Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	71	$1,054,185	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Makenzi Colleen Evangelist, M.D.?

Tedicare shows public-source Medicare data for Makenzi Colleen Evangelist, M.D. (NPI 1578724126), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Makenzi Colleen Evangelist, M.D. have ACO affiliation data?

Makenzi Colleen Evangelist, M.D. is shown with ACO affiliation data for Trinity Health Integrated Care (MSSP, ACO ID A3454).

What billing organization is linked to Makenzi Colleen Evangelist, M.D.?

Makenzi Colleen Evangelist, M.D. is linked to NEW YORK ONCOLOGY HEMATOLOGY, P.C. (billing NPI 1609863448) in the available physician profile data.

Does Makenzi Colleen Evangelist, M.D. have Open Payments data?

Makenzi Colleen Evangelist, M.D. has 83 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.